Cinda Securities releases Morning Light Biotech research report, with full-year profit significantly recovering and an approaching inflection point for price upward movement

NightAirdropper · 2026-04-05T15:20:48+00:00

Everyday AI Express, Cinda Securities released a research report on Morning Light Biotech (300138.SZ, latest price: 12.13 yuan) on April 1: 1) Full-year revenue growth was affected by cottonseed disturbances, but extract sales continued to rise; 2) Full-year gross profit margin saw significant recovery, and net profit attributable to shareholders increased substantially; 3) Dividend payout reached a new high; 4) Q1 2026 performance is expected to be roughly flat year-on-year. Risk warning: product price reductions exceeding expectations, food safety issues.Everyday Headlines (nbdtoutiao)—These "dormant" accounts will be cleaned up! Several banks have announced this recently.(Reporter Wang Hanli)Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Operate at your own risk.Daily Economic News

NightAirdropper

2026-04-05 15:20:48

Jing Daily AI Express: On April 1, China Galaxy Securities published a research report on Arowana Biotech (300138.SZ, latest price: 12.13 yuan): 1) Full-year revenue growth was influenced by cottonseed, while plant-based product sales continued to rise; 2) Full-year gross margin saw a significant rebound, with a large increase in net profit attributable to shareholders; 3) Dividends hit a historical high; 4) The 26Q1 performance is expected to be basically flat year over year. Risk warning: Product price cuts exceed expectations, food safety issues.

Jing Daily Headlines (nbdtoutiao) — These “dormant” accounts will be cleaned up! Several banks have recently announced

(Reporter Wang Hanli)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using. If you act on this, you bear the risk.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.